ClinicalTrials.gg
RecruitingNCT07552038VIH-ODONTOUpdated Jun 25, 2026

Dental Management of Patients With HIV in Pays de la Loire

An observational study in HIV Infection, Acquired Immune Deficiency Syndrome and Oral Health Care, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's listed conditions name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,603
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Acquired Immunodeficiency Syndrome with a site in France — 18 open to participants now, 23 under way, 5 of them phase 3. Acquired Immunodeficiency Syndrome · France.

Planned enrollment
3rd of 34
5,603 · median 250
Started
2026
with 4 others
Observational
34 of 109
11 open now
Primary completion
2027-05
later than 12 of 22 live
Registered
106th of 109
by date
Lead sponsor
3 of 109
Nantes University Hospital

Among the 109 studies in Acquired Immunodeficiency Syndrome with a site in France, this one is the 3rd largest by planned enrollment of the 34 observational ones that give a count, is one of 5 that started in 2026, is one of 34 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 106th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

18 of the 109 studies in Acquired Immunodeficiency Syndrome with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Acquired Immunodeficiency Syndrome with a site in France, or all of them as a file.
02

Study summary

Dental care for people living with HIV has evolved with the widespread use of antiretroviral therapy, which has improved life expectancy and disease control. However, uncertainty remains about whether specific adaptations are still needed during dental procedures due to potential biological abnormalities that may increase infectious or bleeding risks.

This study aims to evaluate the proportion of patients living with HIV in the Pays de la Loire region who may require adapted dental management based on biological parameters such as immune status, hematological values, and comorbidities.

A retrospective descriptive study will be conducted using anonymized data from 5,603 patients followed in the COREVIH Pays de la Loire database. The results are expected to provide objective data to better inform dental practice and reduce unnecessary precautions or stigmatization in the management of patients living with HIV.

Read the detailed description

This is a retrospective descriptive observational study using anonymized data from patients living with HIV followed in the Pays de la Loire region. The dataset includes 5,603 individuals whose data were previously collected as part of routine clinical care and recorded in the Nadis medical database by healthcare professionals involved in HIV management.

Data were provided by the COREVIH Pays de la Loire in an anonymized format and include demographic characteristics (age, sex), HIV-related variables (viral load, duration since diagnosis, antiretroviral therapy status), co-infections (sexually transmitted infections and hepatitis B/C), biological parameters (CD4 lymphocyte count, neutrophil count, platelet count, hemoglobin level), and comorbidities (e.g., diabetes, hypertension, renal disease, cardiovascular conditions, depression).

The primary objective is to determine the proportion of patients presenting biological abnormalities that may increase the risk of infectious or hemorrhagic complications during invasive dental procedures.

Data analysis will consist of descriptive statistics, including frequencies and percentages for categorical variables. The study does not involve any intervention, additional data collection, or direct patient contact.

All data are fully anonymized prior to analysis, ensuring that participants cannot be identified. The study complies with applicable data protection regulations and is based on previously collected clinical data.

03

Conditions studied

  • HIV Infection
  • Acquired Immune Deficiency Syndrome
  • Oral Health Care

Browse trials for

04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 5,603 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients living with HIV followed in hospital-based infectious diseases departments in France, identified retrospectively from routine clinical records and biological databases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged ≥18 years
  • Confirmed diagnosis of infection
  • Followed at participating hospital centers
  • Available clinical and biological data relevant to dental care management (, viral load, blood count)

Exclusion criteria

Exclusion Criteria:

  • Patients with missing key biological data required for analysis
  • Patients not followed in participating centers
  • Patients with incomplete medical records preventing assessment of outcomes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,603 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients With HIV

    Patients living with HIV included in a retrospective cohort using anonymized data from the COREVIH Pays de la Loire database. The study population includes adults followed in routine clinical care, with available demographic, clinical, biological, and comorbidity data used to assess factors relevant to dental management.

    Other: HIV infection status and clinical characteristics

Interventions

  • OtherHIV infection status and clinical characteristics

    Observational assessment of clinical, biological, and comorbidity data in patients living with HIV, including CD4 count, viral load, hematological parameters, and associated conditions, collected from routine care without any intervention.

07

What researchers measure

Primary outcomes

  1. Proportion of Patients Requiring Adapted Dental Management

    Percentage of patients living with HIV presenting at least one biological abnormality associated with increased risk of infectious or hemorrhagic complications during invasive dental procedures, including low CD4 count, neutropenia, thrombocytopenia, or anemia, based on routinely collected clinical data.

    Time frame: At time of data extraction (retrospective baseline)

Secondary outcomes

  1. CD4 Cell Count Distribution

    CD4 lymphocyte count (cells/mm³) distribution among patients, used to assess immune status. Lower values indicate greater immunosuppression.

    Time frame: At time of data extraction (retrospective baseline)

  2. Neutrophil Count Distribution

    Neutrophil count (cells/mm³) measured from routine blood tests. Lower values indicate increased risk of infection.

    Time frame: At time of data extraction (retrospective baseline)

  3. Platelet Count Distribution

    Platelet count (×10⁹/L) measured from routine blood tests. Lower values indicate increased bleeding risk.

    Time frame: At time of data extraction (retrospective baseline)

  4. Hemoglobin Level Distribution

    Hemoglobin level (g/dL) measured from routine blood tests. Lower values indicate anemia.

    Time frame: At time of data extraction (retrospective baseline)

  5. Prevalence of Comorbidities

    Percentage of patients presenting comorbid conditions (e.g., diabetes, cardiovascular disease, renal disease, depression) that may impact dental management.

    Time frame: At time of data extraction (retrospective baseline)

  6. Viral Load Status

    Proportion of patients with detectable versus undetectable HIV viral load, based on routine clinical measurements.

    Time frame: At time of data extraction (retrospective baseline)

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 27, 2026
StartActual
May 2, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552038
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
May 2, 2026
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Gilles Amador del Valle, MD, PhD
Contact
gilles.amadordelvalle@univ-nantes.fr
+33 2 40 08 31 73
Alexandra Poinas, PhD
Contact
alexandra.poinas@chu-nantes.fr
+33 2 53 48 28 57

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion